HeartBeam (BEAT) said Monday its HeartBeam device has received 510(k) clearance from the US Food and Drug Administration for comprehensive arrhythmia assessment.
The device tracks heart signals from three directions to provide heart health information, the company said.
Shares of HeartBeam were up more than 11% in recent premarket activity.